Erratum to: Safety and Tolerability of Fingolimod in Latin American Patients with Relapsing-Remitting Multiple Sclerosis: The Open-Label FIRST LATAM Study

被引：0
作者：
Laura Ordoñez-Boschetti
Roberto Rey
Ana Cruz
Arijit Sinha
Tracy Reynolds
Nadina Frider
Regina Alvarenga
机构：
[1] Consultorio de Medicina Especializada del Sector Privado,
[2] Instituto Argentino de Investigación Neurológica,undefined
[3] Centro de Investigaciones Médicas Hospital Nacional Alberto Sabogal Sologuren,undefined
[4] Novartis Healthcare Pvt. Ltd.,undefined
[5] Novartis Pharma AG,undefined
[6] Novartis LAtinAmerica and Canada Region,undefined
[7] MS Hospital Da Lagoa,undefined
来源：
Advances in Therapy | 2015年 / 32卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：636 / 636
相关论文
共 50 条
  • [21] Safety, Tolerability, and Efficacy of Oral Therapies for Relapsing-Remitting Multiple Sclerosis
    Oh, Jiwon
    O'Connor, Paul W.
    CNS DRUGS, 2013, 27 (08) : 591 - 609
  • [22] Safety, pharmacodynamics, and activity of rituximab in patients with relapsing-remitting multiple sclerosis: a phase I, multicentre, open-label clinical trial
    Bar-Or, A.
    Calabresi, P.
    Arnold, D. L.
    Markowitz, C.
    Shafer, S.
    Kasper, L.
    Waubant, E.
    Gazda, S.
    Fox, R.
    Panzara, M.
    Sarkar, N.
    Agarwal, S.
    Smith, C.
    MULTIPLE SCLEROSIS, 2007, 13 : S165 - S166
  • [23] The experience of using fingolimod (gilenya) in patients with relapsing-remitting multiple sclerosis
    Kotov, S. V.
    Fedorova, S. I.
    Yakushina, T. I.
    Lizhdvoy, V. Yu
    ZHURNAL NEVROLOGII I PSIKHIATRII IMENI S S KORSAKOVA, 2013, 113 (02) : 74 - 78
  • [24] Safety, Tolerability, and Efficacy of Oral Therapies for Relapsing-Remitting Multiple Sclerosis
    Jiwon Oh
    Paul W. O’Connor
    CNS Drugs, 2013, 27 : 591 - 609
  • [25] A phase I, open-label, multicenteir study to evaluate the safety and activity of rituximab in adults with relapsing-remitting multiple sclerosis (RRMS)
    Bar-Or, Amit
    Calabresi, Peter
    Arnold, Douglas
    Markowitz, Clyde
    Shafer, Stuart
    Kasper, Lloyd
    Waubant, Emmanuelle
    Gazda, Suzanne
    Fox, Robert
    Sarkar, Neena
    Panzara, Michael
    Smith, Craig
    NEUROLOGY, 2007, 68 (12) : A84 - A84
  • [26] Efficacy of fingolimod in patients with highly active relapsing-remitting multiple sclerosis
    Derfuss, T.
    Bergvall, N. K.
    Sfikas, N.
    Tomic, D. L.
    CURRENT MEDICAL RESEARCH AND OPINION, 2015, 31 (09) : 1687 - 1691
  • [27] Safety and tolerability of fingolimod 0.5 mg during the first 4 months of administration in patients with relapsing forms of multiple sclerosis. Results from the open-label, multicentre FIRST study
    Kappos, L.
    Comi, G.
    Palace, J.
    Siever, A.
    Marrosu, M.
    Mehling, M.
    Gottschalk, R.
    Bijarnia, M.
    Keil, A.
    Tomic, D.
    von Rosenstiel, P.
    Gold, R.
    JOURNAL OF NEUROLOGY, 2012, 259 : S64 - S65
  • [28] Use of Fingolimod in the Management of Relapsing-Remitting Multiple Sclerosis: Experience from Latin America
    Correale, Jorge
    Flores, Jose
    Garcia Bonitto, Juan
    Carcamo Rodriguez, Claudia
    Oliveira, Enedina M. L.
    ADVANCES IN THERAPY, 2015, 32 (07) : 612 - 625
  • [29] Reasons for switching to fingolimod in patients relapsing-remitting multiple sclerosis in France: the ESGILE study
    Tourbah, Ayman
    Papeix, Caroline
    Tourniaire, Patricia
    Rerat, Karin
    Meite, Mohamed
    Durand, Barbara
    Lamy, Fabienne
    Chouette, Isabelle
    Mekies, Claude
    Aboab, Jennyfer
    Al Khedr, Abdullatif
    Carpentier, Amer Al Najjar
    Androdias, Geraldine
    Benrabah, Rabah
    Biotti, Damien
    Bohotin, Valentin
    Bonnan, Mickael
    Bonnet, Cecilia
    Boulesteix, Jean Marc
    Brassat, David
    Busson, Philippe
    Camu, William
    Castelnovo, Giovanni
    Chapuis, Stephane
    Clavelou, Pierre
    Convers, Philippe
    Coustans, Marc
    Creange, Alain
    Delassaux, Sebastien
    Diot, Eric
    Djerdi, Madjid
    Drouet, Thomas
    Delalande, Sophie Dufour
    Pottier, Corinne Dupel
    Ferriby, Didier
    Gaida, Philippe
    Gal, Guillaume
    Giraud, Pierric
    Guilloton, Laurent
    Hascar, Tijani
    Heinzlef, Olivier
    Rouaud, Violaine Jaffrenou
    Jager, Alain
    Kubler, Christophe
    Le Coz, Patrick
    Frenay, Christine Lebrun
    Maillart, Elisabeth
    Vioud, Paris Marcel Maillet
    Malkoun, Imad
    Manchon, Eric
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 46
  • [30] REALMS study: real-world effectiveness and safety of fingolimod in patients with relapsing-remitting multiple sclerosis in Portugal
    S. Batista
    C. C. Nunes
    J. J. Cerqueira
    Ana Martins Silva
    J. Correia de Sá
    J. Ferreira
    M. T. Mendonça
    J. Pinheiro
    V. Salgado
    A. S. Correia
    J. Sequeira
    A. Costa
    L. Sousa
    Neurological Sciences, 2021, 42 : 1995 - 2003
12345